Vesatolimod clinical trials
Also written GS-9620.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses vesatolimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Gilead Sciences (5) · Aelix Therapeutics (1)
Studies
Open first, then newest update. How each study uses vesatolimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus LevelsTerminatedPhase 1Gilead SciencesNCT05458102Written as Vesatolimod
- Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive PatientsCompletedPhase 2Aelix TherapeuticsNCT04364035Written as GS-9620
- Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected ControllersCompletedPhase 1Gilead SciencesNCT03060447Written as Vesatolimod
- Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed ParticipantsCompletedPhase 2Gilead SciencesNCT02166047Written as Vesatolimod
- Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being TreatedCompletedPhase 2Gilead SciencesNCT02579382Written as Vesatolimod
- Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed AdultsCompletedPhase 1Gilead SciencesNCT02858401Written as Vesatolimod
Given beside what is tested · 2 — vesatolimod is usual care or a partner of the new treatment
- Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1SuspendedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06071767Written as Vesatolimod (VES)
- Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected WomenCompletedPhase 2Gilead SciencesNCT05281510Written as Vesatolimod
Codes
What other systems call vesatolimod · ClinicalTrials.gg INT006319
- MeSH (NLM) C582524vesatolimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) O8M467C50GVESATOLIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q27285487vesatolimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152870VesatolimodOne source FDA
- DrugBank DB12687One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C582524 | vesatolimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | O8M467C50G | VESATOLIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27285487 | vesatolimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152870 | Vesatolimod | One source FDA |
| DrugBank | DB12687 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.